Frequency of extrapyramidal adverse reactions in schizophrenic outpatients treated with risperidone, olanzapine, quetiapine or haloperidol: Results of the EIRE study

Clinical Drug Investigation

Volumn 22, Issue 9, 2002, Pages 609-622

  Bobes, Julio ^a   Rejas, J ^b   Garcia Garcia, M ^c   Rico Villademoros, F ^c   Garcia Portilla M P ^a   Madrigal, M ^b   Hernandez G ^b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b PFIZER INC   (United States)

^c Biometrica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREMOR;

EID: 0036042561     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222090-00006     Document Type: Article

References (44)

1. An overview of side effects caused by typical antipsychotics
2. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia
3. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications
4. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
5. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients
6. Adverse neurobiological effects of long-term use of neuroleptics: Human and animal studies
7. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality
8. The Nithsdale schizophrenia surveys: An overview
9. New atypical antipsychotic medications
10. A five-year follow-up study of tardive dyskinesia
11. Prospective study of tardive dyskinesia incidence in the elderly
12. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
13. Why do schizophrenic patients refuse to take their drugs?
14. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures
15. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment
16. Predictors of therapeutic response to haloperidol in acute schizophrenia
17. Quetiapine Fumarate (Seroquel) a new atypical antipsychotic
18. Severe akathisia during olanzapine treatment of acute schizophrenia
19. Propranolol treatment of olanzapine-induced akathisia
20. Expanding the frontier of treatment research
21. Do phase III trials have clinical value?
22. The UKU side effects rating scale
23. Minimizing the non-extrapyramidal side-effects of antipsychotics
24. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and metaregression analysis
25. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
26. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
27. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
28. Risperidone in the treatment of schizophrenia
29. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
30. An exploratory haloperidol-controlled dose-fixing study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder
31. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel group, double-blind trial
32. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome
33. Dosing the antipsychotic medication olanzapine
34. A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicenter trial
35. The Expert Consensus Guideline Series. Treatment of schizophrenia 1999
36. Ziprasidone
37. Ziprasidone: A new atypical antipsychotic
38. A prospective, multicenter study of patients' refusal of antipsychotic medication
39. Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects
40. Prevalence and extent of distress of adverse reactions of antipsychotics among callers to a United Kingdom National Mental Health Helpline
41. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic